Trial Profile
An open-label, non-randomized, multicenter effectiveness, safety and tolerability study of oxymorphone HCL immediate-release oral liquid in opioid-tolerant pediatric subjects with chronic pain requiring an around the clock opioid.
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase III
Latest Information Update: 22 Aug 2012
Price :
$35
*
At a glance
- Drugs Oxymorphone (Primary)
- Indications Pain
- Focus Therapeutic Use
- 07 Jun 2011 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 29 Sep 2010 New trial record